570 related articles for article (PubMed ID: 20001492)
21. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.
Coppola D; Liu Y; Gopal S; Remmerie B; Samtani MN; Hough DW; Nuamah I; Sulaiman A; Pandina G
BMC Psychiatry; 2012 Mar; 12():26. PubMed ID: 22455454
[TBL] [Abstract][Full Text] [Related]
22. Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability.
Citrome L
Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):873-88. PubMed ID: 22632481
[TBL] [Abstract][Full Text] [Related]
23. A review of paliperidone palmitate.
Chue P; Chue J
Expert Rev Neurother; 2012 Dec; 12(12):1383-97. PubMed ID: 23237346
[TBL] [Abstract][Full Text] [Related]
24. Intramuscular paliperidone palmitate.
Hoy SM; Scott LJ; Keating GM
CNS Drugs; 2010 Mar; 24(3):227-44. PubMed ID: 20155997
[TBL] [Abstract][Full Text] [Related]
25. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study.
Alphs L; Benson C; Cheshire-Kinney K; Lindenmayer JP; Mao L; Rodriguez SC; Starr HL
J Clin Psychiatry; 2015 May; 76(5):554-61. PubMed ID: 25938474
[TBL] [Abstract][Full Text] [Related]
26. Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication.
Citrome L
Int J Clin Pract; 2010 Jan; 64(2):216-39. PubMed ID: 19886879
[TBL] [Abstract][Full Text] [Related]
27. Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release.
Boom S; Talluri K; Janssens L; Remmerie B; De Meulder M; Rossenu S; van Osselaer N; Eerdekens M; Cleton A
J Clin Pharmacol; 2009 Nov; 49(11):1318-30. PubMed ID: 19713555
[TBL] [Abstract][Full Text] [Related]
28. Paliperidone extended-release for the treatment of schizophrenia.
Marino J; Caballero J
Pharmacotherapy; 2008 Oct; 28(10):1283-98. PubMed ID: 18823223
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States.
Citrome L; Kamat SA; Sapin C; Baker RA; Eramo A; Ortendahl J; Gutierrez B; Hansen K; Bentley TG
J Med Econ; 2014 Aug; 17(8):567-76. PubMed ID: 24758296
[TBL] [Abstract][Full Text] [Related]
30. Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia.
Carter NJ
Drugs; 2012 May; 72(8):1137-60. PubMed ID: 22571444
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.
Marder SR; Kramer M; Ford L; Eerdekens E; Lim P; Eerdekens M; Lowy A
Biol Psychiatry; 2007 Dec; 62(12):1363-70. PubMed ID: 17601495
[TBL] [Abstract][Full Text] [Related]
32. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia.
Berwaerts J; Cleton A; Rossenu S; Talluri K; Remmerie B; Janssens L; Boom S; Kramer M; Eerdekens M
J Psychopharmacol; 2010 Jul; 24(7):1011-8. PubMed ID: 19825908
[TBL] [Abstract][Full Text] [Related]
33. Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia.
Canuso CM; Bossie CA; Amatniek J; Turkoz I; Pandina G; Cornblatt B
Early Interv Psychiatry; 2010 Feb; 4(1):64-78. PubMed ID: 20199482
[TBL] [Abstract][Full Text] [Related]
34. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study.
Kramer M; Litman R; Hough D; Lane R; Lim P; Liu Y; Eerdekens M
Int J Neuropsychopharmacol; 2010 Jun; 13(5):635-47. PubMed ID: 19941696
[TBL] [Abstract][Full Text] [Related]
35. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia.
Fleischhacker WW; Gopal S; Lane R; Gassmann-Mayer C; Lim P; Hough D; Remmerie B; Eerdekens M
Int J Neuropsychopharmacol; 2012 Feb; 15(1):107-18. PubMed ID: 21777507
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone.
Laffont CM; Gomeni R; Zheng B; Heidbreder C; Fudala PJ; Nasser AF
J Clin Pharmacol; 2015 Jan; 55(1):93-103. PubMed ID: 25043337
[TBL] [Abstract][Full Text] [Related]
37. The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets.
Berwaerts J; Cleton A; Herben V; van de Vliet I; Chang I; van Hoek P; Eerdekens M
Pharmacopsychiatry; 2009 Jul; 42(4):158-63. PubMed ID: 19585395
[TBL] [Abstract][Full Text] [Related]
38. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia.
Luthringer R; Staner L; Noel N; Muzet M; Gassmann-Mayer C; Talluri K; Cleton A; Eerdekens M; Battisti WP; Palumbo JM
Int Clin Psychopharmacol; 2007 Sep; 22(5):299-308. PubMed ID: 17690599
[TBL] [Abstract][Full Text] [Related]
39. Paliperidone: quo vadis?
Citrome L
Int J Clin Pract; 2007 Apr; 61(4):653-62. PubMed ID: 17343660
[TBL] [Abstract][Full Text] [Related]
40. Practical guidelines on the use of paliperidone palmitate in schizophrenia.
Newton R; Hustig H; Lakshmana R; Lee J; Motamarri B; Norrie P; Parker R; Schreiner A
Curr Med Res Opin; 2012 Apr; 28(4):559-67. PubMed ID: 22321007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
